GLP-1 Peptide Atlas, by Delfa

CompletedPhase 2, PHASE3Results posted

Semaglutide in CFRD

Efficacy and Safety of GLP-1 Agonist Therapy in Overweight and Obese Subjects With Cystic Fibrosis-related Diabetes: a Pilot Study

Lead sponsor

University of Minnesota

Assets

GLP-1 / incretin class catch-all / Semaglutide

Listed sites

Recruiting sites

—

Enrollment

actual

Study population

Cystic Fibrosis, Diabetes (other / unspecified), Obesity / overweight

Key I/E criterion

•BMI ≥26

Primary endpoints

•Body weight, absolute change (kg)•BMI, change

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT05788965

Org study IDMED-2023-29616

Timeline

Milestones

Study first posted2023-03-29actual

Study start2023-10-16actual

Primary completion2024-12-23actual

Study completion2024-12-31actual

Last update posted2026-01-21actual

Results first posted2026-01-21actual

Assets

Investigational agents

GLP-1 / incretin class catch-all Semaglutide

Study populations

Who this study enrolls

Cystic FibrosisDiabetes (other / unspecified)Obesity / overweight

Eligibility

Who can enroll

Minimum age18 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Adult subjects 18 years or older with CFRD and on insulin treatment

•BMI >26 kg/m2

•Diagnosis of pancreatic insufficiency (based on treatment with pancreatic enzyme replacement therapy)

•A participant who is capable of becoming pregnant must agree to take precautions that are effective in preventing pregnancy throughout this study. These methods could include one of the following 1. Complete abstinence from sexual intercourse; 2. Oral, injectable, or implanted hormonal contraceptives 3. Intrauterine device 4. Tubal ligation

Exclusion criteria

•personal or family history of medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2 (MEN2)

•acute pulmonary exacerbation requiring IV antibiotics or systemic glucocorticoids within 4 weeks prior to baseline study procedures

•gastrointestinal(GI) symptom exacerbation defined by current nausea/vomiting or diarrhea at the baseline assessment

•history of chronic GI problems requiring hospitalization in the 1 year prior to baseline

•history of clinically symptomatic pancreatitis

•history of clinically significant gastroparesis

•history of eating disorders

•less than 24 weeks since start of a new CFTR corrector/modulator therapy

•pregnancy or lactation

•severe CF liver disease

•chronic kidney disease

•history of suicide attempts or active suicidal ideation

•Non-English speakers and those unable to read in English

Endpoints (8)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Weight & body composition

Glycemic / diabetes

Weight & body composition

4 endpoints

Primary/registry result

Weight

Time frame:12 weeks

Body weight, absolute change (kg)

change from baseline, improvement

Posted result

Group	Value (mean), kilograms	95% CI
Semaglutide Treatment	-4.6	—

Primary/registry result

BMI (kg/m2)

Time frame:12 weeks

BMI, change

change from baseline, improvement

Posted result

Group	Value (mean), kg/m2	95% CI
Semaglutide Treatment	-1.8	—

Primary/protocol endpoint

Weight

Time frame:12 weeks

Body weight, absolute change (kg)

change from baseline, improvement

Primary/protocol endpoint

BMI (kg/m2)

Time frame:12 weeks

BMI, change

change from baseline, improvement

Glycemic / diabetes

4 endpoints

Secondary/registry result

CGM % Time in Target TIR)

Time frame:12 weeks

CGM time-in-range

change from baseline, improvement

Posted result

Group	Value (mean), percentage time in target	95% CI
Semaglutide Treatment	7	—

Secondary/registry result

A1c

Time frame:12 weeks

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Posted result

Group	Value (mean), change in the percent of HbA1c	95% CI
Semaglutide Treatment	-0.3	—

Secondary/protocol endpoint

CGM % Time in Target TIR)

Time frame:12 weeks

CGM time-in-range

change from baseline, improvement

Secondary/protocol endpoint

A1c

Time frame:12 weeks

HbA1c, % change

percent change from baseline, improvement

LOINC 4548-4

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableClinicalTrials.gov results section

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.